Minghui Pharmaceutical (Hangzhou) is the lead sponsor of 14 current clinical trials in our China register. 12 are recruiting patients now. The most common phase is Phase 1/2. The drugs named most often in its trials are MHB039A, MHB018A and MHB036C. The most-studied condition is Advanced Malignant Solid Tumor.
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
A Study of MHB048C in Patients With Advanced Solid Tumors
NCT07192120 · mCRPC (Metastatic Castration-resistant Prostate Cancer), Advanced Malignant Solid Tumor
|
Phase 1/2 | Recruiting | 2026-01 | China |
|
A Phase III Clinical Study to Evaluate the Efficacy and Safety of MH004 Ointment in Non-segmental Vitiligo
NCT07682506 · ClinicalTrials.gov ↗ · Vitiligo
|
Phase 3 | Recruiting | 2026-08 | China |
|
A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer
NCT07229599 · ClinicalTrials.gov ↗ · Advanced Lung Cancer
|
Phase 1/2 | Recruiting | 2025-05 | China |
|
A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors
NCT07130383 · ClinicalTrials.gov ↗ · Advanced Breast Cancer, Advanced Malignant Solid Tumor
|
Phase 2 | Recruiting | 2025-09 | China |
|
A Study of MHB042C in Patients With Advanced Solid Tumors
NCT07192107 · ClinicalTrials.gov ↗ · Advanced Malignant Solid Tumor
|
Phase 1/2 | Recruiting | 2025-11 | China |
|
A Study of MHB088C Combined With MHB039A in Patients With Advanced Malignant Solid Tumors
NCT07126665 · ClinicalTrials.gov ↗ · Advanced Malignant Solid Tumor
|
Phase 1/2 | Recruiting | 2025-09 | China |
|
Open-Label Extension Study of MHB018A in Subjects With Thyroid Eye Disease
NCT07262476 · ClinicalTrials.gov ↗ · Thyroid Eye Disease (TED)
Drug: MHB018A |
Phase 3 | Recruiting | 2026-01 | China |
|
A Study of MHB009C in Patients With Advanced Solid Tumors
NCT07326488 · ClinicalTrials.gov ↗ · Advanced Malignant Solid Tumor
|
Phase 1/2 | Recruiting | 2026-03 | China |
|
A Study of MHB118C Injection in Patients With Advanced Solid Tumors
NCT07045454 · ClinicalTrials.gov ↗ · Advanced Malignant Solid Tumor
|
Phase 1 | Recruiting | 2025-03 | China |
|
A Study of MHB046C Injection in Patients With Advanced Solid Tumors
NCT06985355 · ClinicalTrials.gov ↗ · Advanced Solid Cancer
|
Phase 1/2 | Recruiting | 2025-07 | China |
|
MHB018A Treatment in Patients With Active Thyroid Eye Disease
NCT06989918 · ClinicalTrials.gov ↗ · Thyroid Associated Ophthalmopathies
Drug: MHB018A |
Phase 3 | Recruiting | 2025-07 | China |
|
MHB018A Treatment in Patients With Chronic Thyroid Eye Disease
NCT07257185 · ClinicalTrials.gov ↗ · Thyroid Eye Disease (TED)
Drug: MHB018A |
Phase 3 | Recruiting | 2026-03 | China |
|
A Study of MHB036C for Advanced Solid Tumor
NCT06373406 · ClinicalTrials.gov ↗ · Advanced Solid Tumor
Drug: MHB036C |
Phase 1/2 | Active, closed | 2023-05 | China |
|
A Study of MHB039A for Advanced Solid Tumor
NCT06345482 · ClinicalTrials.gov ↗ · Advanced Solid Tumor
Drug: MHB039A |
Phase 1/2 | Active, closed | 2024-04 | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 14 | 12 |
A trial with sites in more than one country appears in each of those registers.
| Sponsor | Trials |
|---|---|
| Sinocelltech | 2 |
| Jiangsu Alphamab Biopharmaceuticals | 2 |
| Suzhou Maximum Bio-tech | 1 |
Sponsors with the most current trials registered for this condition.
Minghui Pharmaceutical (Hangzhou) is the lead sponsor of 14 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 12 of its 14 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Its current trials name 6 drugs and biologicals as interventions. The most frequent are MHB039A (4), MHB018A (3), MHB036C (3), Carboplatin (1) and Furmonertinib (1). The number in brackets is how many of its trials name each drug.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.